Serbia is expanding its laboratory and research capacity, putting greater emphasis on the commercial value that can emerge from publicly supported scientific work. The development creates a policy challenge extending beyond research infrastructure. Patents, companies and future revenues generated through publicly funded laboratories and grants will require clear ownership arrangements between researchers, institutions and private investors.
Technology transfer becomes a governance priority
Public authorities can more readily measure investment in physical research infrastructure and grants than the commercialisation of scientific discoveries. Laboratory construction, procurement and research funding operate through established administrative processes, while technology transfer requires universities to assess intellectual property, negotiate with founders and investors and manage projects where commercial failure is common. The ownership of commercially valuable research is particularly complex when discoveries are developed using public equipment and grant funding. Researchers, institutions and external investors can potentially have competing interests in the resulting intellectual property.
Restrictive ownership arrangements could discourage scientists from establishing companies, while excessively favourable terms could leave the public sector bearing development costs without an appropriate share of the resulting commercial value. Predictable ownership percentages and rapid decision-making can allow companies to be established while market opportunities remain available.
Technology-transfer offices need commercial expertise
Serbia’s technology-transfer offices will face a broader role as research infrastructure expands. Rather than functioning primarily as administrative units, they will need to identify potentially patentable research, assess market demand, locate corporate partners and negotiate licensing agreements. That work requires a combination of legal, scientific and business-development expertise. Serbia has limited experience operating this type of multidisciplinary technology-transfer structure at scale.
The commercialisation process also depends on the people leading spin-out companies. Scientific expertise does not necessarily translate into executive management capabilities, creating a need for experienced entrepreneurs, executives-in-residence and venture investors who can build management teams around promising technologies.
Public research must reach commercial markets
The ownership issue extends beyond startup policy because the location of commercial value determines where the economic returns from publicly funded research ultimately accrue. If inventions produced through Serbian public research are consistently commercialised abroad, domestic institutions could finance the costly early stages of development while companies and other jurisdictions capture the resulting corporate value.
At the same time, institutions that retain discoveries too tightly could prevent technologies from reaching the market. The policy challenge is therefore to establish mechanisms through which research can move efficiently from laboratories into companies while maintaining an appropriate public return. The BIO4 project will place these questions within a larger research and commercialisation ecosystem. Its capacity to generate Serbian-owned intellectual property will depend not only on laboratory infrastructure but also on the ownership arrangements governing discoveries developed within it.
